NASDAQ:GNCA
Delisted
Genocea Biosciences Stock News
$0.0001
+0 (+0%)
At Close: Apr 19, 2023
Genocea Biosciences Is Shutting Down. What GNCA Stock Investors Should Know.
10:38am, Wednesday, 25'th May 2022
Genocea Biosciences (GNCA) stock is on the move Wednesday after the bioscience company revealed its shutting down and delisting shares. The post Genocea Biosciences Is Shutting Down.
Benzinga's Top Ratings Upgrades, Downgrades For April 29, 2022
02:03pm, Friday, 29'th Apr 2022 Benzinga
Upgrades
Fox Advisors upgraded the previous rating for Seagate Technology Holdings PLC (NASDAQ:STX) from Equal-Weight to Overweight. Seagate Tech Hldgs earned $1.81 in the third quarter, compared to $
Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives
08:05pm, Thursday, 28'th Apr 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that
Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes
01:36pm, Monday, 11'th Apr 2022 PennyStocks
What you need to know about trading penny stocks on April 11th
The post Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Informat
Implied Volatility Surging for Genocea (GNCA) Stock Options
12:49pm, Monday, 11'th Apr 2022 Zacks Investment Research
Investors need to pay close attention to Genocea (GNCA) stock based on the movements in the options market lately.
Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes
09:36am, Monday, 11'th Apr 2022
What you need to know about trading penny stocks on April 11th The post Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Informat
Genocea Presents Encouraging Initial Data from GEN-011 Phase 1/2a Trial at AACR 2022
05:05pm, Friday, 08'th Apr 2022 GlobeNewswire Inc.
GEN-011 shows consistent pattern of activity in first five heavily pre-treated, checkpoint-refractory patients with advanced solid tumors and progressive disease
Genocea Biosciences Stock Dives After Early Data From GEN-011 Trial In Pretreated Solid Tumor Patients
02:35pm, Friday, 08'th Apr 2022
Genocea Biosciences Inc (NASDAQ: GNCA) has shared initial data from Phase 1/2a TiTAN trial OF GEN-011 in patients with refractory solid tumors. The company says that the early results presented at
Genocea Biosciences to Host Investor Webinar
12:07pm, Monday, 04'th Apr 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced deta
Genocea to Present at the 32nd Annual Oppenheimer Healthcare Conference
09:06pm, Monday, 14'th Mar 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that
Genocea to Present at the 32nd Annual Oppenheimer Healthcare Conference
05:06pm, Monday, 14'th Mar 2022
CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that C
Genocea Biosciences, Inc. (GNCA) CEO William Clark on Q4 2021 Results - Earnings Call Transcript
03:25pm, Thursday, 10'th Mar 2022 Seeking AlphaGenocea Biosciences GAAP EPS of -$0.19 misses by $0.01
12:02pm, Thursday, 10'th Mar 2022 Seeking Alpha
Genocea Biosciences press release (GNCA): Q4 GAAP EPS of -$0.19 misses by $0.01.Cash and cash equivalents of $37.1M.The company''s existing cash is sufficient to support…
Genocea Biosciences, Inc. (GNCA) CEO William Clark on Q4 2021 Results - Earnings Call Transcript
10:25am, Thursday, 10'th Mar 2022
Genocea Biosciences, Inc. (GNCA) CEO William Clark on Q4 2021 Results - Earnings Call Transcript
Earnings Scheduled For March 10, 2022
09:33am, Thursday, 10'th Mar 2022 Benzinga
Companies Reporting Before The Bell • Despegar.com (NYSE: DESP ) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares UltraShort Russell2000 (NYSE: TWM ) is expected to report earnings for its fourth quarter. • Vivid Seats (NASDAQ: SEAT ) is projected to report quarterly loss at $0.07 per share on revenue of $139.54 million. • LumiraDx (NASDAQ: LMDX ) is expected to report quarterly loss at $0.09 per share on revenue of $69.60 million. • Life Time Group Hldgs (NYSE: LTH ) is expected to report quarterly loss at $0.41 per share on revenue of $356.92 million. • ATRenew (NYSE: RERE ) is likely to report quarterly loss at $0.03 per share on revenue of $368.91 million. • FuelCell Energy (NASDAQ: FCEL ) is estimated to report quarterly loss at $0.05 per share on revenue of $26.73 million. • Zealand Pharma (NASDAQ: ZEAL ) is expected to report quarterly loss at $0.93 per share on revenue of $11.98 million. • Yatsen Holding (NYSE: YSG ) is projected to report quarterly loss at $0.